Fox Chase Cancer Center News

Survey From Fox Chase and Other Institutions Finds Majority of Practitioners in Hereditary Gastroenterology Support Use of Genetic Testing to Determine Colorectal Cancer Risk, Treatment

PHILADELPHIA (October 30, 2023) — A majority of clinicians with expertise in hereditary gastroenterology support implementing genetic screening known as universal germline testing for the diagnosis of colorectal cancer, according to the results of a clinical practice survey conducted by Sanjeevani Arora, PhD, an Assistant Professor in the Cancer Prevention and Control Research Program at Fox Chase Cancer Center.
VIEW STORY

Researcher at Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center Awarded $100,000 Grant From Mary Kay Ash Foundation for Breast Cancer Work

PHILADELPHIA (October 26, 2023) — Lucia Borriello, PhD, an Assistant Professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University and a member of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, has been awarded a $100,000 Mary Kay Ash Foundation Innovative/Translational Cancer Research Grant.
VIEW STORY

African-Caribbean Cancer Consortium Holds 8th Annual Conference, Honors Researchers With Awards

PHILADELPHIA (October 19, 2023) — The African-Caribbean Cancer Consortium (AC3), which was formed in 2006 to further the study of viral, genetic, environmental, and lifestyle risk factors for cancer in populations of African descent, held its 8th annual conference recently in Mombasa, Kenya. Several researchers were recognized for their work and dedication to the AC3’s mission.
VIEW STORY

Fox Chase Cancer Center Invests in Expanding Access to Lifesaving Radiopharmaceuticals for Cancer Patients

PHILADELPHIA (October 17, 2023) — As the first initiative of an emerging collaboration, Fox Chase Cancer Center has invested in Nucleus RadioPharma, a company specializing in the development and distribution of radiopharmaceuticals, targeted therapies that deliver radiation directly to cancer cells. The company’s technology platform is considered to be at the forefront of radiopharmaceutical research and designed to advance new therapies from clinical trials to commercialization. Fox Chase and Nucleus also have signed a Letter of Intent to potentially enable to a deeper collaboration, including partnership in developing a radiopharmaceutical manufacturing site and clinical trials involving radiopharmaceuticals.
VIEW STORY